Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium

Australian Ovarian Cancer Study Group(QIMR Berghofer Medical Research Institute), Christina M. Nagle(QIMR Berghofer Medical Research Institute), Suzanne C. Dixon‐Suen(The University of Queensland), Allan Jensen(Danish Cancer Society), Susanne K. Kjær(University of Copenhagen), Francesmary Modugno(University of Pittsburgh), Anna DeFazio(Millennium Institute), Sián Fereday(Peter MacCallum Cancer Centre), Jillian A. Hung(Millennium Institute), Sharon E. Johnatty(University of California, Los Angeles), Peter A. Fasching(University of California, Los Angeles), MW Beckmann(Friedrich-Alexander-Universität Erlangen-Nürnberg), Diether Lambrechts(KU Leuven), Ignace Vergote(KU Leuven), Els Van Nieuwenhuysen(KU Leuven), Sandrina Lambrechts(Yale University), Harvey A. Risch(Yale University), Mary Anne Rossing(Dartmouth College), Jennifer A. Doherty(Dartmouth College), Kristine G. Wicklund(German Cancer Research Center), Jenny Chang‐Claude(Cedars-Sinai Medical Center), Marc T. Goodman(Cedars-Sinai Medical Center), R. B. Ness(Roswell Park Comprehensive Cancer Center), Kirsten B. Moysich(Roswell Park Comprehensive Cancer Center), Florian Heitz(Helios Dr. Horst Schmidt Kliniken Wiesbaden), Andreas du Bois(Helios Dr. Horst Schmidt Kliniken Wiesbaden), Philipp Harter(Helios Dr. Horst Schmidt Kliniken Wiesbaden), Ira Schwaab(Kyushu University), Keitaro Matsuo(Kyushu University), Satoyo Hosono(Aichi Cancer Center), Ellen L. Goode(Mayo Clinic in Florida), Robert A. Vierkant(Mayo Clinic in Florida), Melissa C. Larson(University of Kansas), Brooke L. Fridley(University of Copenhagen), Claus Høgdall(University of Copenhagen), Joellen M. Schildkraut(Duke Medical Center), Rachel Palmieri Weber(Brigham and Women's Hospital), Daniel W. Cramer(Brigham and Women's Hospital), Kathryn L. Terry(Rutgers, The State University of New Jersey), Elisa V. Bandera(Rutgers, The State University of New Jersey), Lisa E. Paddock(Rutgers, The State University of New Jersey), Lorna Rodríguez-Rodríguez(Rutgers, The State University of New Jersey), Nicolas Wentzensen(National Institutes of Health), Hannah Yang(National Institutes of Health), Louise A. Brinton(National Institutes of Health), Jolanta Lissowska(University of Copenhagen), Estrid Høgdall(University of Copenhagen), Lene Lundvall(University of Copenhagen), Alice S. Whittemore(Stanford University), Valerie McGuire(Stanford University), Weiva Sieh(Stanford University), Joseph H. Rothstein(University of South Florida), Rebecca Sutphen(University of California, Irvine), Hoda Anton‐Culver(University of California, Irvine), Argyrios Ziogas(University of Southern California), Celeste Leigh Pearce(University of Southern California), Anna H. Wu(University of Southern California), Penelope M. Webb(The University of Queensland)
British Journal of Cancer
July 7, 2015
10.1038/bjc.2015.245
Cited by 157Open Access
Full Text

Abstract

BACKGROUND: Observational studies have reported a modest association between obesity and risk of ovarian cancer; however, whether it is also associated with survival and whether this association varies for the different histologic subtypes are not clear. We undertook an international collaborative analysis to assess the association between body mass index (BMI), assessed shortly before diagnosis, progression-free survival (PFS), ovarian cancer-specific survival and overall survival (OS) among women with invasive ovarian cancer. METHODS: We used original data from 21 studies, which included 12 390 women with ovarian carcinoma. We combined study-specific adjusted hazard ratios (HRs) using random-effects models to estimate pooled HRs (pHR). We further explored associations by histologic subtype. RESULTS: Overall, 6715 (54%) deaths occurred during follow-up. A significant OS disadvantage was observed for women who were obese (BMI: 30-34.9, pHR: 1.10 (95% confidence intervals (CIs): 0.99-1.23); BMI: ⩾35, pHR: 1.12 (95% CI: 1.01-1.25)). Results were similar for PFS and ovarian cancer-specific survival. In analyses stratified by histologic subtype, associations were strongest for women with low-grade serous (pHR: 1.12 per 5 kg m(-2)) and endometrioid subtypes (pHR: 1.08 per 5 kg m(-2)), and more modest for the high-grade serous (pHR: 1.04 per 5 kg m(-2)) subtype, but only the association with high-grade serous cancers was significant. CONCLUSIONS: Higher BMI is associated with adverse survival among the majority of women with ovarian cancer.

Related Papers

No related papers found

Powered by citation graph analysis